Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial.
To evaluate whether 550 mg oral naproxen sodium given 1 hour before intrauterine device (IUD) insertion is effective for pain relief as compared with placebo.



This was a randomized, double-blind, placebo-controlled trial. The primary outcome was pain with IUD insertion measured on a 100-mm visual analog scale (VAS). Our sample size was calculated to detect a 15-mm difference in VAS scores with 80% power (α=0.05). Secondary outcomes included pain with tenaculum placement, uterine sounding, and 5 and 15 minutes postinsertion.



A total of 118 women were enrolled and analyzed (58 in the naproxen sodium arm, 60 in the placebo arm, 97% nulliparous) between May 11, 2015, and March 25, 2016. There were no differences in baseline demographics or reproductive characteristics between arms. There were no differences in median VAS pain scores for the primary outcome of pain with IUD insertion between the naproxen sodium arm compared with the placebo arm (69 compared with 66 mm, P=.89). There were no differences in the secondary outcomes of median VAS pain scores with tenaculum placement (37 compared with 32 mm, P=.97) or uterine sounding (60 compared with 58 mm, P=.66). However, median pain scores postprocedure were lower in the naproxen arm as compared with the placebo arm: 17 compared with 26 mm (P=.01) at 5 minutes and 13 compared with 24 mm (P=.01) at 15 minutes postinsertion.



Oral naproxen sodium does not reduce pain with IUD insertion but does reduce pain after insertion and should be considered as a premedication.



ClinicalTrials.gov, http://clinicaltrials.gov, NCT02388191.
Department of Obstetrics, Gynecology, and Reproductive Biology, and the Center for Clinical Investigation, Brigham and Women's Hospital, and Planned Parenthood League of Massachusetts, Boston, Massachusetts.
Lynn L
LL
Ngo
Kari P
KP
Braaten
Eva
E
Eichen
Jennifer
J
Fortin
Rie
R
Maurer
Alisa B
AB
Goldberg
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects*; D009288:Naproxen / Q000008:administration & dosage / Q000627:therapeutic use*; D010146:Pain / Q000517:prevention & control*; D010147:Pain Measurement; D013997:Time Factors; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009288:Naproxen